Pyxis Oncology, Inc. 8-K/A

What Happened
Pyxis Oncology, Inc. (PYXS) filed an 8‑K reporting that, effective April 29, 2026, Dr. Sullivan’s separation agreement with the company became binding and she resigned from the Board of Directors. The filing states her resignation was not due to any dispute or disagreement with the company or its board.

Key Details

• Separation effective date: April 29, 2026; 8‑K filed April 30, 2026.
• Salary continuation: Dr. Sullivan will continue to receive her existing salary for 18 months post‑Effective Date.
• Benefits: Continued health coverage for up to 12 months.
• Equity: The Compensation Committee approved accelerated vesting of all her unvested restricted stock units and unvested stock options, and extended the post‑termination exercise period for those accelerated options to December 31, 2030.
• Covenants: One‑year post‑separation non‑solicitation covenant (applicable to Dr. Sullivan) and a one‑year mutual non‑disparagement covenant.

Why It Matters
For investors, this filing shows Pyxis has contractual cash and benefit obligations (salary continuation and health coverage) and has accelerated equity vesting, which adjusts her equity entitlement and option exercise timeline. The company also confirms the resignation was not due to any disagreement with management or board, which is a disclosure investors watch for governance or management stability signals.